Cilosta100 mg

Cilosta 100 mg is indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.

Peripheral Vasodilator drugs: Intermittent Claudication

Cilosta 100 mg is a preparation of Cilosta 100 mg which is a quinolinone derivative. The mechanism of action is to specifically inhibit cellular phosphodiesterase III (PDE III) and suppress cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.

The recommended dosage of Cilosta 100 mg is 100 mg bid, taken at least half an hour before or two hours after breakfast and dinner. A dose of 50 mg bid should be considered during coadministration of Fluconazole, Ketoconazole, Itraconazole, Erythromycin, Clarithromycin, Fluvoxamine, Fluoxetine, Nefazodone, Sertraline and Diltiazem.

The recommended dosage of Cilosta 100 mg is 100 mg bid, taken at least half an hour before or two hours after breakfast and dinner. A dose of 50 mg bid should be considered during coadministration of Fluconazole, Ketoconazole, Itraconazole, Erythromycin, Clarithromycin, Fluvoxamine, Fluoxetine, Nefazodone, Sertraline and Diltiazem.Pediatric use: The safety and effectiveness of Cilosta 100 mg in pediatric patients have not been established.

Pharmacokinetic studies have demonstrated that Omeprazole and Erythromycin significantly increased the systemic exposure of Cilosta 100 mg and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of Cilosta 100 mg among patients concurrently treated with Diltiazem.

Cilosta 100 mg is contraindicated in patients with congestive heart failure of any severity. Cilosta 100 mg is also contraindicated in patients with known or suspected hypersensitivity to any of its components.

The most common side effects are headache, diarrhoea, vomiting, leg cramps, rash etc. The less frequent side effects are anorexia and edema.

There are no adequate and well controlled studies in pregnant women. Transfer of Cilosta 100 mg into milk has been reported in experimental animals. Because of the potential risk to nursing infants, a decision should be made to discontinue nursing or to discontinue Cilosta 100 mg.

Cilosta 100 mg should be used with caution in patients with any degree of heart failure. There is no information with respect to the efficacy or safety of the concurrent use of Cilosta 100 mg and Clopidogrel.

Severe headache, diarrhoea, hypotension, tachycardia, and possibly cardiac arrhythmias. Careful observation and supportive treatment are recommended.

Store in a cool & dry place, protected from light and moisture.

Paediatric use: The safety and effectiveness of Cilosta 100 mg in paediatric patients have not been established.

Peripheral Vasodilator drugs: Intermittent Claudication

Cilosta 100 mg is a preparation of Cilosta 100 mg which is a quinolinone derivative. The mechanism of action is to specifically inhibit cellular phosphodiesterase III (PDE III) and suppress cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.

There are no adequate and well controlled studies in pregnant women. Transfer of Cilosta 100 mg into milk has been reported in experimental animals. Because of the potential risk to nursing infants, a decision should be made to discontinue nursing or to discontinue Cilosta 100 mg.